Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma

Nicola Amodio, Maria Teresa Di Martino, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone

Research output: Contribution to journalArticlepeer-review


Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
Issue numberSUPPL.1
Publication statusPublished - Jun 2013


  • MicroRNA
  • MiRNA
  • MiRNA therapeutics
  • Multiple myeloma
  • Non coding RNA

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery


Dive into the research topics of 'Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this